Molecular Medicine Commemorates the Achievements of the First 20 Years by Ruggieri, M.
Journal Articles Donald and Barbara Zucker School of MedicineAcademic Works
2015
Molecular Medicine Commemorates the
Achievements of the First 20 Years
M. Ruggieri
Hofstra Northwell School of Medicine
Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for
inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works.
Recommended Citation
Ruggieri M. Molecular Medicine Commemorates the Achievements of the First 20 Years. . 2015 Jan 01; 21(Suppl 1):Article 90 [ p.].
Available from: https://academicworks.medicine.hofstra.edu/articles/90. Free full text article.
To celebrate the 20th anniversary of
Molecular Medicine, this special issue
showcases the fields of science influ-
enced by the most cited scientific contri-
butions to the journal over the past two
decades. The authors of these reviews
are leaders in the fields of immunology,
cancer, atherosclerosis, Alzheimer’s dis-
ease and diabetes. We asked them to pro-
vide updates that highlight the progress
made in the selected fields of research to
which their highly cited Molecular Medi-
cine publication contributed.
Two reviews discuss key elements in
the immune response to tissue injury: one
focuses on the fibrocyte, which acts dur-
ing the earliest phase of the innate im-
mune response, and the other focuses on
HMGB1, which acts as a later mediator
of inflammation. Richard Bucala reports
on the advances made on the “fibrocyte,”
the unique collagen-producing leukocyte
that he discovered in the 1990s and its
role beyond the original context of
wound repair. The contribution of this
cell type to the pathogenesis of different
fibrosing disorders has led to fibrocyte-
directed therapies that are currently
being tested in the clinic. Huan Yang and
colleagues provide an overview of
HMGB1, a later mediator of infection
and tissue injury. The authors review its
multiple functions and complex regula-
tion. They conclude with a discussion on
the first two HMGB1-specific  antagonists
that are paving the way toward future
therapeutic applications.
A third review by Antonino Nicoletti
and colleagues looks at the adaptive im-
mune response in the context of athero-
sclerosis. The authors discuss the roles
that proatherogenic and athero-protective
T and B cells play in this disease. They
also highlight the different strategies
used in preclinical studies with an out-
look to clinical applications.
Jason A Chesney and Robert A
Mitchell follow the saga of macrophage
migration inhibitory factor (MIF) from
its discovery through the many studies
that implicate this cytokine in several as-
pects of cancer biology. They focus in
particular on the role of MIF in tumor
neovascularization, which likely partici-
pates in primary and metastatic disease
progression. The advances made in this
field are underscored by the first clinical
trial that has been initiated to test anti-
MIF therapies.
Jennifer Hardingham and colleagues
cover the circulating tumor cells (CTCs),
another interesting aspect of cancer biol-
ogy with great implications for clinical
applications. Their discussion of various
technical efforts that have been made to
capture these cells from the patients’
blood, the advances made and the chal-
lenges that still remain offer a clear pic-
ture of the state of the art of this new ap-
proach. These advances will certainly
augment the battery of cancer diagnostic
tools in the clinic in the not too distant
future.
Sho-ichi Yamagishi and colleagues
tackle the role of advanced glycation end
products (AGEs) in diabetes. They de-
scribe how the products of reactions oc-
curring between sugars and proteins,
lipids and nucleic acids lead to altered
function and metabolism of these macro-
molecules with severe consequences in
diabetes and aging-associated disorders.
The authors also discuss the potential
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value of measuring serum levels of AGEs
to evaluate organ damage in diabetes.
Finally, Jochen Walter summarizes the
incredible progress made over the past
two decades in understanding the role of
presenilins in the onset of Alzheimer’s
disease. From the discovery of the gene
mutations in inherited familial forms of
early onset of Alzheimer’s disease, Wal-
ter follows the path of discoveries that
leads to the identification of their func-
tions as components of a protease com-
plex responsible for the cleavage of the
amyloid precursor protein, an important
determinant of the pathophysiology of
the disease. He also discusses the hopes
associated with the development of sev-
eral inhibitors of presenilins and the dis-
appointing results of their use in the
clinic. Dr. Walter concludes with a posi-
tive outlook on development of more se-
lective inhibitors of presenilins that
could provide future therapies for Alz-
heimer’s disease.
We are pleased to offer these engaging
and interesting historical perspectives of
fields that were introduced to the scien-
tific public in our journal and hope that
our readers will enjoy them, too.
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